SCHEMBL2986897

SCHEMBL2986897

CCC(CC)C(=O)Nc1ccc(C(=O)CN2C(=O)C(c3ccccc3)(c3ccccc3)N=C2C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.50
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
RAB9A P51151 1/20 0.44
ALDH1A1 P00352 4/20 0.40
BACE1 P56817 2/20 0.40
BACE2 Q9Y5Z0 1/20 0.40
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
CTSD P07339 1/20 0.39
CTSE P14091 1/20 0.39
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA14 Q9ULX7 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
GAA P10253 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2972354 0.87 SMN1; SMN2 (0.47) SMN1; SMN2MEN1KMT2ARAB9AALDH1A1
SCHEMBL2982195 0.85 NPY2R (0.41) SMN1; SMN2MEN1KMT2ABACE1CTSD
SCHEMBL2985223 0.84 MEN1 (0.46) SMN1; SMN2MEN1KMT2ARAB9AALDH1A1
SCHEMBL2983850 0.83 MEN1 (0.46) SMN1; SMN2MEN1KMT2ARAB9AALDH1A1
SCHEMBL2983179 0.82 NPC1 (0.49) SMN1; SMN2MEN1KMT2ARAB9AMAPT
SCHEMBL2985753 0.81 BACE1 (0.46) SMN1; SMN2KMT2ARAB9ABACE1BACE2
SCHEMBL2978004 0.81 KMT2A (0.43) MEN1KMT2ARAB9AALDH1A1MAPT
SCHEMBL3659352 0.80 MEN1 (0.56) SMN1; SMN2MEN1KMT2APOLB
SCHEMBL2989532 0.80 BACE1 (0.50) SMN1; SMN2RAB9ABACE1BACE2MAPT
SCHEMBL2982704 0.79 MAPT (0.52) SMN1; SMN2MEN1KMT2ARAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7786155-B2 Organic compounds NOVARTIS AG (CH) 2010-08-31 US claimed
US-7786155-B2 Organic compounds NOVARTIS AG (CH) 2010-08-31 US disclosed
EP-2212295-A2 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF Novartis AG (CH) 2010-08-04 EP disclosed
WO-2009050201-A2 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF NOVARTIS AG (CH) 2009-04-23 WO disclosed
US-20090099244-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099244-A1 ORGANIC COMPOUNDS SLCO4C1, SLC10A6, SLCO1B1 SMN1; SMN2 4082/4885MEN1 235/4885KMT2A 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.